Type6 Therapeutics is a biotechnology company developing small-molecule kinase inhibitors that stabilize disease-driving kinases in their inactive OFF-states
Type6 Therapeutics is a biotechnology company developing small-molecule kinase inhibitors that stabilize disease-driving kinases in their inactive OFF-states. Its platform combines bivalent chemistry, computational biology, and allostery-aware drug design to pursue selective, durable treatments for kinase-addicted cancers. Its lead program targets CDK2, with a pipeline vision spanning additional kinases and potential applications in other disease areas.